A case of neonatal fatty acid oxidation disorder

Ling-Li DENG, Hong-Mei ZOU, Ting-Ting CHENG, Yuan YUAN, Hua-Yan ZHANG

Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (6) : 768-771.

PDF(503 KB)
HTML
PDF(503 KB)
HTML
Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (6) : 768-771. DOI: 10.7499/j.issn.1008-8830.2511087
CASE REPORT

A case of neonatal fatty acid oxidation disorder

Author information +
History +

Abstract

A full-term male neonate, aged 2 days, was admitted for jaundice lasting more than 2 days. On the day of admission, he developed sudden respiratory arrest and shock; vital signs were restored after active resuscitation. The acylcarnitine profile showed markedly elevated long-chain acylcarnitines, including C16∶1, C18, and C18∶1, indicating a fatty acid oxidation disorder and raising suspicion for carnitine-acylcarnitine translocase deficiency or carnitine palmitoyltransferase II deficiency. Whole-exome sequencing identified compound heterozygous variants in SLC25A20: c.823C>T (p.Arg275Ter) and c.199-10T>G, classified as likely pathogenic and pathogenic, respectively, confirming carnitine-acylcarnitine translocase deficiency. On day 50 of life, infection precipitated a metabolic crisis with recurrent shock; considering the poor prognosis, the family chose to withdraw treatment, and the patient died on day 52 of life. Carnitine-acylcarnitine translocase deficiency is a congenital fatty acid oxidation disorder. Neonatal fatty acid oxidation disorders typically have acute onset, rapid progression, and atypical manifestations, predisposing to misdiagnosis and poor prognosis. This case may serve as a reference for the clinical recognition and management of neonatal fatty acid oxidation disorders.

Key words

Fatty acid oxidation disorder / Carnitine-acylcarnitine translocase deficiency / SLC25A20 gene / Neonate

Cite this article

Download Citations
Ling-Li DENG , Hong-Mei ZOU , Ting-Ting CHENG , et al . A case of neonatal fatty acid oxidation disorder[J]. Chinese Journal of Contemporary Pediatrics. 2026, 28(6): 768-771 https://doi.org/10.7499/j.issn.1008-8830.2511087

References

[1]
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424. PMCID: PMC4544753. DOI: 10.1038/gim.2015.30 .
[2]
Wang GL, Wang J, Douglas G, et al. Expanded molecular features of carnitine acyl-carnitine translocase (CACT) deficiency by comprehensive molecular analysis[J]. Mol Genet Metab, 2011, 103(4): 349-357. DOI: 10.1016/j.ymgme.2011.05.001 .
[3]
Yan HM, Hu H, Ahmed A, et al. Carnitine-acylcarnitine translocase deficiency with c.199-10T>G and novel c.1A>G mutation: two case reports and brief literature review[J]. Medicine (Baltimore), 2017, 96(45): e8549. PMCID: PMC5690761. DOI: 10.1097/MD.0000000000008549 .
[4]
Marsden D, Bedrosian CL, Vockley J. Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders[J]. Genet Med, 2021, 23(5): 816-829. PMCID: PMC8105167. DOI: 10.1038/s41436-020-01070-0 .
[5]
Rubio-Gozalbo ME, Bakker JA, Waterham HR, et al. Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects[J]. Mol Aspects Med, 2004, 25(5/6): 521-532. DOI: 10.1016/j.mam.2004.06.007 .
[6]
Ryder B, Inbar-Feigenberg M, Glamuzina E, et al. New insights into carnitine-acylcarnitine translocase deficiency from 23 cases: management challenges and potential therapeutic approaches[J]. J Inherit Metab Dis, 2021, 44(4): 903-915. DOI: 10.1002/jimd.12371 .
[7]
Li X, Shen J. One potential hotspot SLC25A20 gene variants in Chinese patients with carnitine-acylcarnitine translocase deficiency[J]. Front Pediatr, 2022, 10: 1029004. PMCID: PMC9676358. DOI: 10.3389/fped.2022.1029004 .
[8]
Spiekerkoetter U. Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening[J]. J Inherit Metab Dis, 2010, 33(5): 527-532. DOI: 10.1007/s10545-010-9090-x .
[9]
Al-Sannaa NA, Cheriyan GM. Carnitine-acylcarnitine translocase deficiency. Clinical course of three Saudi children with a severe phenotype[J]. Saudi Med J, 2010, 31(8): 931-934.
[10]
Vockley J. Long-chain fatty acid oxidation disorders and current management strategies[J]. Am J Manag Care, 2020, 26(7 ): S147-S154. PMCID: PMC9850137. DOI: 10.37765/ajmc.2020.88480 .
Suppl
[11]
Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders[J]. Annu Rev Physiol, 2002, 64: 477-502. DOI: 10.1146/annurev.physiol.64.082201.154705 .
[12]
Costa C, Costa JM, Slama A, et al. Mutational spectrum and DNA-based prenatal diagnosis in carnitine-acylcarnitine translocase deficiency[J]. Mol Genet Metab, 2003, 78(1): 68-73. DOI: 10.1016/s1096-7192(02)00205-6 .
[13]
Wilcken B, Haas M, Joy P, et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study[J]. Lancet, 2007, 369(9555): 37-42. DOI: 10.1016/S0140-6736(07)60029-4 .

Footnotes

所有作者声明无利益冲突。

PDF(503 KB)
HTML

Accesses

Citation

Detail

Sections
Recommended

/